D. E. Shaw & Co., Inc. Vertex Pharmaceuticals Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $4.19 Million - $4.6 Million	9,100 Added 182.0%	14,100 $6.56 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $1.53 Million - $1.89 Million	-3,900 Reduced 43.82%	5,000 $2.34 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $3.63 Million - $3.97 Million	8,900 New	8,900 $3.72 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $153,390 - $181,860	-600 Reduced 4.14%	13,900 $3.78 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $112,740 - $147,900	-500 Reduced 3.33%	14,500 $4.21 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $998,850 - $1.24 Million	-5,000 Reduced 25.0%	15,000 $3.57 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $1.34 Million - $1.54 Million	-8,000 Reduced 28.57%	20,000 $3.86 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.17 Million - $1.36 Million	8,000 Added 40.0%	28,000 $4.76 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $1.52 Million - $1.77 Million	-10,000 Reduced 33.33%	20,000 $3.26 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $4.44 Million - $4.87 Million	30,000	30,000 $4.56 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.